ConvaTec reported ostomy findings and ConvaTec stock fell 1.54 percent

Published on 10/08/2026 at 18:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The survey covered 1,841 patients and 431 clinicians on October 6, 2026. ConvaTec stock costs EUR 2.55 on October 8, 2026 after EUR 2.59.

Key points in brief

ConvaTec reported ostomy survey findings based on 1,841 people and 431 healthcare professionals on October 6, 2026.
ConvaTec stock was trading at EUR 2.55 at Lang & Schwarz on October 8, 2026, down 1.54 percent from EUR 2.59.
Continence revenue reached USD 277.00 million in the first half of 2026, up 6.60 percent year over year.
The stock's primary listing is on the London Stock Exchange and it is a FTSE 100 constituent.

Editorialfoto vom Handelssaal der Londoner Börse mit Gesundheitssektor-Charts — ConvaTec Group Plc GB00BD3VFW73 zeigt Börsen-Editorial vom Handelssaal der London Stock Exchange mit Gesundheitssektor-Charts, Illustration mit AI erstellt.

ConvaTec stock was trading at EUR 2.55 at Lang & Schwarz on October 8, 2026 in after-hours trading, down 1.54 percent versus the prior close of EUR 2.59. ConvaTec had reported new ostomy-care research on October 6, 2026, with findings based on 1,841 people living with an ostomy and 431 healthcare professionals, according to Business Wire.

What the survey measured

The research found that more than half of respondents had experienced ostomy leakage in the past year, while nearly two thirds reported under-baseplate leakage within the previous month. Nearly four in ten respondents reported peristomal skin problems during the past 12 months, placing skin health at the center of the company's ostomy-care message.

The commercial backdrop is measurable. ConvaTec's continence care revenue reached USD 277.00 million in the first half of 2026, up 6.60 percent from the same period of 2025, according to Medical Tubing and Extrusion. The same report described Cure Aqua as a ready-to-use hydrophilic catheter launched in the United States and Canada.

Three dated company developments

On September 11, 2026, Berenberg cut its ConvaTec price target from GBp 340.00 to GBp 335.00 while keeping a Buy rating, as reported by MarketBeat. On September 28, 2026, the company launched Cure Aqua in North America, while the October 6 survey added evidence on ostomy-care needs.

What comes next for ConvaTec?

The next dated company event listed by onvista is the fiscal-year 2026 report scheduled for February 23, 2027. Until then, the key investor tension is visible in the contrast between 6.60 percent continence revenue growth in the first half of 2026 and the current 1.54 percent decline in the euro reference quote.

Stock trades below yearly high

On the London Stock Exchange, ConvaTec's quoted share price was GBp 216.60 on October 7, 2026, against a 52-week range of GBp 193.00 to GBp 259.30. Its market capitalization was EUR 4.9 billion as of October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of ConvaTec stock.